Compound for inhibiting nutrient absorption of small intestines and application
By inhibiting the absorption of nutrients of small intestine, the lack of treatment of obesity and blood lipids in the prior art is solved, and significantly lowering blood lipids and weight is provided, providing a new method for treating obesity.
Patent Information
- Application Number
- CN202411124414.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art is relatively limited in treating obesity and reducing blood lipids, and lacks safe and effective interventions, which leads to obesity posing a serious threat to human health.
Develop a complex that inhibits the absorption of nutrients in small intestine, including GABA and 6-hydroxyflavonoids (6-HF), to achieve lipid reduction by inhibiting the length of the small intestine microvilli, reducing the surface area of the small intestine nutrient absorption, and reducing the absorption rate of lipid nutrients by the small intestine. and weight loss effects.
This complex significantly reduces blood lipid levels and loses weight, providing a new strategy for treating obesity. By regulating the microvilli structure of small intestinal epithelial cells, reducing the absorption of lipid nutrients, significantly enhancing the physiological regulatory effect of GABA, and is used to prepare Health foods and drugs used to lower blood lipids and treat obesity.
Smart Images

Figure CN118986960A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of health products and medicines, and in particular relates to a compound for inhibiting small intestinal nutrient absorption and an application thereof. Background Art
[0002] Obesity is a pathological condition caused by a variety of factors that disrupts the body's energy metabolism, leading to an increase in fat cell volume or adipose tissue content exceeding normal levels, which affects the body's health. Obesity, as a disease of lipid metabolism disorder, seriously threatens human health. Genetics, lifestyle, eating habits and environmental factors can all cause obesity.
[0003] Blood lipids refer to the general term for lipids contained in the blood, including triglycerides (TG), cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), etc. Their levels in the blood are affected by age, gender, dietary composition, lipid metabolism function, genetic factors, mental activity and disease and are in dynamic balance. With the improvement of living standards, changes in dietary structure, alcoholism, etc., are accompanied by high blood lipids, high blood pressure, high blood sugar, etc. Among them, high blood lipids are the culprit of various cardiovascular and cerebrovascular diseases such as cerebral thrombosis and coronary heart disease, which seriously affects people's health. However, the current means of treating obesity and effectively losing weight are relatively limited. Therefore, in order to improve the quality of life of the people, improve their health, and prevent chronic diseases, it is urgent to explore new strategies for obesity treatment and develop safer and more effective obesity intervention methods. Summary of the invention
[0004] The present invention provides a compound for inhibiting small intestinal nutrient absorption and its application. The compound can inhibit the length of small intestinal microvilli, reduce the surface area of small intestinal nutrient absorption and reduce the absorption rate of lipid nutrients in the small intestine, thereby achieving the effect of reducing fat and / or losing weight.
[0005] The present invention provides a compound for inhibiting small intestinal nutrient absorption, which comprises GABA and 6-hydroxyflavone (6-HF).
[0006] Preferably, the molar ratio of GABA to 6-hydroxyflavone (6-HF) in the complex is 1:(10-18).
[0007] Preferably, the inhibition of small intestinal nutrient absorption includes at least one of the following: (1) inhibiting the length of small intestinal microvilli;
[0008] (2) Reduce the surface area for nutrient absorption in the small intestine;
[0009] (3) Reduce the absorption rate of lipid nutrients in the small intestine.
[0010] The present invention provides the use of the above-mentioned complex in the preparation of health food, wherein the health food has at least one of the following effects: (a) helping to regulate body fat;
[0011] (b) Helps maintain healthy blood lipid levels;
[0012] (c) Lose weight.
[0013] The invention provides a health food comprising the above compound.
[0014] The present invention also provides the use of the above-mentioned complex in the preparation of a drug, wherein the efficacy of the drug includes at least one of the following:
[0015] ①Lowering blood lipids;
[0016] ② Lose weight;
[0017] ③Treatment of obesity.
[0018] The present invention also provides a drug for lowering blood lipids and / or treating obesity, comprising the above-mentioned complex and pharmaceutically acceptable excipients.
[0019] Beneficial effects: The present invention provides a complex for inhibiting small intestinal nutrient absorption, which includes GABA and 6-hydroxyflavone (6-HF). In the embodiment, 0.5 μM GABA and 5 μM 6-HF can achieve a significant inhibitory effect on small intestinal absorption, and 6-HF can significantly amplify the physiological regulatory effect of GABA; the subcellular structure of the microvilli of the small intestinal epithelial cells can be regulated to reduce the absorption surface area of the small intestinal epithelial cells, thereby inhibiting the small intestine's absorption capacity for lipid nutrients, reducing blood lipids, reducing body weight, and treating obesity. The complex can be prepared as a health product or medicine for inhibiting small intestinal nutrient absorption, lowering blood lipids, and treating obesity, providing a new idea for the treatment of obesity. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 GABA provided by the present invention A The expression results of receptors in the intestine, among which Figure A shows the GABA expressed by fluorescent tracer mice (Gabra1-Cre; Rosa26-tdTomato) A Receptor expression levels (top), GABA A The expression level of the receptor gradually increased in the duodenum, jejunum, ileum, colon, and rectum, showing a positive correlation with the abundance of intestinal flora (Figure below);
[0021] Figure 2 The antibiotics provided by the present invention remove intestinal flora and have an effect on small intestinal GABA A Receptor expression and lipid nutrient absorption, among which Figure A shows small intestinal GABA AFigure B is the fluorescence result of receptor expression level; Figure B is the result of blood lipid level; Figure C is the result of triglyceride absorption by the small intestine;
[0022] Figure 3 The results of the length of small intestinal microvilli are shown in Figure A, where Figure A is a representative electron microscope image of small intestinal microvilli; Figure B is a statistical analysis of the distribution ratio of the length of small intestinal microvilli;
[0023] Figure 4 GABA provided by the present invention A Electrophysiological results of receptor cells, where A is the structural formula of compound 6-HF; B is the degree of inhibition of electrophysiological activity of cells after incubation with GABA (left); co-incubation of GABA and 6-HF can amplify the inhibitory effect of GABA on cell electrophysiological activity (right);
[0024] Figure 5 The electrophysiological results of brain slices provided by the present invention are shown in Figure A; wherein Figure A is GABA A The expression distribution of receptors in the whole brain; Figure B is the electrophysiological results of DMV nucleus neurons in brain slice electrophysiological recordings before and during compound incubation; Figure C is the electrophysiological action potential frequency analysis; Figure D is the electrophysiological membrane potential mean analysis; Figure E is the statistical analysis of the percentage of neuronal depolarization.
[0025] Figure 6 The present invention provides an analysis of the body weight, blood lipids, and small intestinal fat absorption capacity of obese mice after intraperitoneal injection of 6-HF; wherein A is a flow chart of intraperitoneal injection; B is a weight curve; C is a blood lipid level result diagram; D is a result diagram of triglyceride absorption by the small intestine; E is a representative diagram of the electron microscopy results of small intestinal microvilli; F is a distribution ratio analysis of the length of small intestinal microvilli; and G is the average value of the length of small intestinal microvilli. DETAILED DESCRIPTION
[0026] The present invention provides a compound for inhibiting small intestinal nutrient absorption, which comprises GABA and 6-HF.
[0027] In the present invention, the small intestinal cells bulge into the intestinal cavity to form a villus structure. Multiple cells together constitute the small intestinal villus structure, which expands the absorption surface area of the small intestine by nearly 10 times; the cell membrane of the small intestinal epithelial cells forms a subcellular ultrastructure - microvilli with a length of 1 to 2 μm and a diameter of 0.1 μm, which further expands the absorption surface area of the small intestine by 9 to 16 times; the two-level bulge structure extends the absorption surface area of the small intestine by nearly 100 times, allowing the nutrients in the diet to fully contact the small intestine and promote digestion and absorption.
[0028] The complex of the present invention can inhibit nutrient absorption in the small intestine, and preferably includes at least one of the following: (1) inhibiting the length of small intestinal microvilli;
[0029] (2) Reduce the surface area for nutrient absorption in the small intestine;
[0030] (3) Reduce the absorption rate of lipid nutrients in the small intestine.
[0031] The molar ratio of GABA to 6-HF in the complex of the present invention is preferably 1:(10-18), more preferably 1:10. In the embodiment, 0.5 μM GABA and 5 μM 6-HF can achieve the most significant inhibition of small intestinal absorption, and 6-HF can significantly increase the physiological regulatory effect of GABA.
[0032] The present invention provides the use of the above-mentioned complex in the preparation of health food, wherein the health food has at least one of the following effects: (a) helping to regulate body fat;
[0033] (b) Helps maintain healthy blood lipid levels;
[0034] (c) Lose weight.
[0035] In the complex of the present invention, 6-HF can enhance GABA by changing the receptor topology. A The present invention demonstrates that 6-HF can enhance the binding ability of GABA receptors to ligands. A The receptor binds to its ligand and promotes the opening of the chloride channel.
[0036] The compound of the present invention, GABA A The receptor is used as an intervention target to regulate the length of intestinal microvilli, change the absorption surface area, and inhibit nutrient absorption in the small intestine; and the 6-HF in the complex acts on the GABA in the DMV nucleus of the brainstem A The receptor regulates the length of intestinal microvilli through the vagus nerve, reduces the intestinal absorption surface area and inhibits the absorption of nutrients in the small intestine. The regulation of the length of microvilli by the compound 6-HF can be achieved through the control of the brainstem DMV nucleus to the small intestinal epithelial cells.
[0037] The invention provides a health food, comprising the above compound and food-acceptable auxiliary materials.
[0038] The present invention does not specifically limit the types of the health food, and preferably includes foods with lipid-lowering and weight-loss effects, candies, functional drinks, and food additives.
[0039] The present invention also provides the use of the above-mentioned complex in the preparation of a drug, wherein the efficacy of the drug includes at least one of the following:
[0040] ①Lowering blood lipids;
[0041] ② Lose weight;
[0042] ③Treatment of obesity.
[0043] The composite of the present invention has been shown in the examples to have the effects of lowering blood lipids, reducing weight and treating obesity, and can be used in the preparation of medicines.
[0044] The present invention also provides a drug for lowering blood lipids and / or treating obesity, comprising the above-mentioned complex and pharmaceutically acceptable excipients.
[0045] In order to further illustrate the present invention, a composite for inhibiting small intestinal nutrient absorption and its application provided by the present invention are described in detail below in conjunction with examples, but they should not be construed as limiting the protection scope of the present invention.
[0046] Example 1
[0047] GABA A The Gabra1-Cre and Rosa26-tdTomato receptor fluorescent tracing mice (Gabra1-Cre; Rosa26-tdTomato) were constructed by the inventors and Saiye Biotechnology Co., Ltd. The Cre element was inserted into the promoter of the endogenous Gabra1 gene of mice using CRISPR / Cas9 technology, and the expression of the Cre element was driven by the endogenous Gabra1 promoter. After three generations of genetic screening of the mouse model, it was confirmed that Gabra1-Cre can be stably expressed in the mouse genome; the mice were mated with the tool mice Rosa26-tdTomato (purchased from the international animal model sharing and communication platform Jackson Laboratory) to obtain GABA A Receptor fluorescent tracing mice (Gabra1-Cre; Rosa26-tdTomato). The obese mouse model was established by high-fat feeding for 8 weeks in an SPF animal room (60% fat content, Research Diet, catalog number: D12492), and experimental operations such as feeding, cage changing, anesthesia, analgesia, and sacrifice of experimental animals were carried out in accordance with relevant animal ethics regulations.
[0048] 1. GABA A Intestinal expression analysis of receptors
[0049] The fluorescent tracer mice were sacrificed and the duodenum, jejunum, ileum, colon, and rectum were collected. After each section of the intestinal tissue was fixed with formaldehyde, dehydrated, embedded in OCT, and frozen sectioned, the fluorescence expression of the small intestinal tissue was analyzed using a confocal microscope. Figure 1 As shown, intestinal GABA A The expression ratio of receptor cells was positively correlated to a certain extent with the abundance of intestinal flora in each segment.
[0050] 2. Effect of antibiotics on small intestinal GABA A Effects of receptor expression, physiological function, and microvilli length
[0051] Antibiotics (1 mg / mL gentamicin, 0.25 mg / mL vancomycin) were added to drinking water to inhibit GABA A The mice were treated with gastrointestinal flora clearance for 2 weeks, and the expression of GABA in epithelial cells was compared between the antibiotic and control groups by red fluorescence. A The ratio of receptors changes ( Figure 2 (A).
[0052] The changes in physiological indicators of mice in the antibiotic group and the control group were detected. The physiological indicators involved in the present invention include postprandial blood lipid levels ( Figure 2 B), triglyceride levels absorbed by the small intestine ( Figure 2 C), quantitative small intestine's ability to absorb lipid nutrients. Subcellular structures such as intestinal microvilli were detected by transmission electron microscopy, and the distribution ratio of microvilli length was statistically analyzed ( Figure 3 Middle AB) to clarify the changes in the absorptive surface area of the small intestine.
[0053] The physiological indicators involved in the present invention include: triglyceride (TG) content in samples such as plasma and intestinal tissue, and the determination method is as follows: weigh 20-30 mg of sample, add 5% NP40 lysis solution, heat at 95°C for 5 minutes, and repeat twice; after cooling to room temperature, centrifuge the sample at 15000 rpm for 5 minutes, use the Biovision kit, take 2 μl of the sample supernatant through the display reaction, quantify with an enzyme marker, and then use the protein concentration of each sample for correction to calculate the triglyceride content of each group of samples.
[0054] Table 1 Postprandial blood lipid levels (mM)
[0055]
[0056]
[0057] Table 2 Small intestinal triglyceride content (μmol / mg protein)
[0058]
[0059] Table 3 Distribution ratio of small intestinal microvilli length (%)
[0060]
[0061] 3. Compound 6-HF acts on GABA A Experimental verification of the physiological function of the receptor
[0062] Patch clamp technology is a technology for recording the electrophysiological activities of cell membrane ion channels. This technology can accurately monitor the electrophysiological activities of cells and link molecules with cells and physiological functions.
[0063] The present invention uses lentivirus to transfect Gabra1, Gabrb3, and Gabrg2 in HEK293 cell lines, and screens the protein expressed in the cell lines to obtain stable clones expressing GABA A GABA receptor (α1β3γ2) cell line, using patch clamp technique to record A Cellular electrophysiological activity of receptors during drug incubation. In the present invention, 0.5 μM GABA incubation was used as a control, and 5 μM 6-HF + 0.5 μM GABA co-incubation can produce 2 to 3 times the chloride ion current; the compound 6-HF can significantly amplify the current caused by the natural ligand GABA, causing the cells to enter a stronger inhibitory state ( Figure 4 (middle B).
[0064] 4. Functional verification of compound 6-HF in brain tissue
[0065] In the central nervous system, GABA A The receptor is highly expressed in the brainstem DMV nuclei ( Figure 5 (A) Therefore, we focused on the dorsal nucleus of the vagus nerve and used brain slice electrophysiology to clarify the physiological regulatory function of the compound 6-HF on the brainstem DMV.
[0066] After the mouse model was deeply anesthetized with isoflurane, artificial cerebrospinal fluid (ACSF) was perfused through the heart with pre-cooled water to maintain the neuronal state of the brain tissue. The brain was quickly removed, sliced, and incubated. The brain slices were fixed in the recording bath through the perfusion system, and the current at the baseline level and during the incubation period was continuously recorded using a patch clamp system (Molecular Devices Axon 700B). Figure 5 In the present invention, the baseline of brain slice neurons was recorded using current clamp mode for 2-3 min, compound 6-HF (5 μM) was incubated for 5-20 min, and the electrophysiological activity during the artificial cerebrospinal fluid washout process ( Figure 5 B), and counted the frequency of the two-phase action potentials ( Figure 5 C) and cell membrane potential ( Figure 5 (middle D).
[0067] Table 4 Electrophysiological action potential frequency and cell membrane potential
[0068]
[0069]
[0070] Table 5 Number and percentage of inhibited neurons after incubation with compound 6-HF
[0071] Number of neurons 100% Neuronal depolarization 25 80.65% Non-depolarizing 6 19.35%
[0072] 5. Changes of 6-hydroxyflavone on small intestinal surface area and nutrient absorption in animal models
[0073] In the following examples, 6-hydroxyflavone was intraperitoneally injected in an animal model to clarify its regulation of small intestinal microvilli, reduction of small intestinal absorptive surface area, and inhibition of lipid nutrient absorption.
[0074] C57BL / 6J mice (8 weeks old) were purchased from Weitong Lihua Experimental Animal Technology Co., Ltd. and fed with high-fat diet for 8 weeks in an SPF animal room until their body weight reached 35 g. The initial body weight of the mice before administration was recorded. Figure 6 As shown in A, 6-HF and saline were intraperitoneally injected daily, and the body weight changes were recorded ( Figure 6 B); Determination of blood lipid levels ( Figure 6 C) and the small intestine triglyceride content after a meal to quantify the small intestine's fat absorption capacity ( Figure 6 Middle D). Subcellular structures such as intestinal microvilli were detected using transmission electron microscopy ( Figure 6 E), and the distribution ratio of microvilli length ( Figure 6 Middle F), average length of small intestinal microvilli ( Figure 6 (G) Statistical analysis was performed to clarify the changes in the small intestinal absorptive surface area.
[0075] Table 6 Percentage change of body weight curve (%)
[0076]
[0077]
[0078] Table 7 Postprandial blood lipid levels (mM)
[0079]
[0080] Table 8 Small intestinal triglyceride content (μmol / mg protein) Table 9 Distribution ratio of small intestinal microvilli length (%)
[0081]
[0082] Table 10 Average length of small intestinal microvilli (nm)
[0083]
[0084] In summary, the present invention shows that the flavonoid compound 6-HF can achieve metabolic benefits such as lowering blood lipids and reducing body weight by regulating the subcellular structure of small intestinal microvilli, reducing the absorption surface area, and inhibiting the efficiency of small intestinal nutrient absorption. Therefore, the flavonoid compound 6-HF and its analogs can be used to prepare blood lipid-lowering and obesity treatment drugs.
[0085] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. A compound for inhibiting nutrient absorption in the small intestine, characterized in that: The complex includes GABA and 6-hydroxyflavone.
2. The composite according to claim 1, characterized in that The molar ratio of GABA to 6-HF in the complex is 1:(10-18).
3. The composite according to claim 1, characterized in that The inhibition of small intestinal nutrient absorption includes at least one of the following: (1) inhibiting the length of small intestinal microvilli; (2) Reduce the surface area for nutrient absorption in the small intestine; (3) Reduce the absorption rate of lipid nutrients in the small intestine.
4. Use of the complex according to any one of claims 1 to 3 in the preparation of health food, characterized in that: The health food has at least one of the following effects: (a) helps regulate body fat; (b) Helps maintain healthy blood lipid levels; (c) Lose weight.
5. A health food, characterized in that: The invention comprises the complex according to any one of claims 1 to 3.
6. Use of the complex according to any one of claims 1 to 3 in the preparation of a drug, characterized in that: The efficacy of the drug includes at least one of the following: ①Lowering blood lipids; ② Lose weight; ③Treatment of obesity.
7. A drug for lowering blood lipids and / or treating obesity, characterized in that: The invention comprises the complex according to any one of claims 1 to 3 and pharmaceutically acceptable excipients.
